Yuxue Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuxue Cao has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Amirali Popat
The University of Queensland
3 shared publications - Taskeen Iqbal Janjua
School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Brisbane, Australia
2 shared publications - Chengzhong Yu
The University of Queensland
1 shared publication - Jared Adam Miles
The University of Queensland, Faculty of Health and Behavioural Sciences
1 shared publication Jason Ward
School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia
1 shared publication- Liam Krueger
School of Pharmacy, The University of Queensland, Brisbane, Australia
1 shared publication
Latest Publications
- Open Access
- 29 August 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (61) , e74760
Advanced Materials for Biologics Delivery to Brain Tumors
Brain cancer remains a major global health challenge due to its high morbidity and mortality. Current standard therapies are often limited by incomplete tumor resection, systemic toxicity, and the inability to effectively penetrate the blood‐brain barrier (BBB), which restricts drug delivery to the tumor site. These challenges underscore the urgent need for innovative therapeutic strategies that can overcome these barriers and improve treatment outcomes. Biological materials encompass a diverse range of molecules, from small peptides to monoclonal antibodies, either derived from living organisms or synthetically synthesized. Unlike traditional therapies, biologics provide a more targeted approach, including specific tumor targeting, immune system modulation, and regenerating damaged cells. Although biologics offer significant promise for brain cancer treatment, major challenges associated with blood–brain and tumour barriers continue to limit their translation, and comprehensive reviews bridging therapeutic advances with delivery technologies remain scarce. While individual biologic classes have been extensively studied, a unified assessment of these modalities and their delivery optimization is still needed. This review addresses the current gap by critically examining recent advances in biologic therapies and evaluating emerging invasive and non‐invasive delivery strategies to enhance their therapeutic efficacy in brain cancer.
- 29 August 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (61) , e74760
Open AccessAdvanced Materials for Biologics Delivery to Brain Tumors
Brain cancer remains a major global health challenge due to its high morbidity and mortality. Current standard therapies are often limited by incomplete tumor resection, systemic toxicity, and the inability to effectively penetrate the blood‐brain barrier (BBB), which restricts drug delivery to the tumor site. These challenges underscore the urgent need for innovative therapeutic strategies that can overcome these barriers and improve treatment outcomes. Biological materials encompass a diverse range of molecules, from small peptides to monoclonal antibodies, either derived from living organisms or synthetically synthesized. Unlike traditional therapies, biologics provide a more targeted approach, including specific tumor targeting, immune system modulation, and regenerating damaged cells. Although biologics offer significant promise for brain cancer treatment, major challenges associated with blood–brain and tumour barriers continue to limit their translation, and comprehensive reviews bridging therapeutic advances with delivery technologies remain scarce. While individual biologic classes have been extensively studied, a unified assessment of these modalities and their delivery optimization is still needed. This review addresses the current gap by critically examining recent advances in biologic therapies and evaluating emerging invasive and non‐invasive delivery strategies to enhance their therapeutic efficacy in brain cancer.
- 30 July 2024
- Published by University of Queensland Library
Smart Silica nanoparticles for oral biologics delivery
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- 30 July 2024
- Published by University of Queensland Library
Smart Silica nanoparticles for oral biologics delivery
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- Open Access
- 12 June 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 642, 123132
3D printing tablets for high-precision dose titration of caffeine
- 12 June 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 642, 123132
Open Access3D printing tablets for high-precision dose titration of caffeine
- Top Cited Papers
- 7 October 2021
- Published by Springer Nature in Nature Reviews Materials
- Vol. 6 (12) , 1072-1074
Clinical translation of silica nanoparticles
Silica nanoparticles have entered clinical trials for a variety of biomedical applications, including oral drug delivery, diagnostics, plasmonic resonance and photothermal ablation therapy. Preliminary results indicate the safety, efficacy and viability of silica nanoparticles under these clinical scenarios.
- 7 October 2021
- Published by Springer Nature in Nature Reviews Materials
- Vol. 6 (12) , 1072-1074
Top Cited PapersClinical translation of silica nanoparticles
Silica nanoparticles have entered clinical trials for a variety of biomedical applications, including oral drug delivery, diagnostics, plasmonic resonance and photothermal ablation therapy. Preliminary results indicate the safety, efficacy and viability of silica nanoparticles under these clinical scenarios.